. . . . . "S&T TWOC Project - version 4" . "S&T TWOC version 3" . "2"^^ . "2023-07-20T09:47:12.861646"^^ . . . "for COVID-19 therapy" . "(477, 490)" . "considered" . "498" . "other antibiotics like azithromycin , ivermectin , eravacycline , valrubicin , streptomycin , nitazoxanide , teicoplanin , caspofungin , and colistin ; and other agents like hydroxychloroquine , chloroquine , tocilizumab , camostat , nafamostat , carfilzomib , interferon , aprepitant , and dexamethasone" . "(477, 490)" . "Results Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy." . "8j41d0a3" . "8j41d0a3-TRIPLE-ABSTRACT-2" . "dexamethasone" . "therapy" . "RSA" . "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" . "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" . . .